Continued Overall Survival Benefit After 5 Years’ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies...

Konference: 2011 53rd ASH Annual Meeting – účast ČR

Kategorie: Mnohočetný myelom

Téma: 653. Myeloma - Therapy, excluding Transplantation I

Číslo abstraktu: 476

Autoři: Prof. M.D. Jesús San Miguel, Ph.D.; MD Rudolf Schlag; MD Nuriet K. Khuageva; Meletios Athanasios Dimopoulos, MD; MD Ofer Shpilberg, MPH; MD Martin (H.) Kropff; Prof.MUDr. Ivan Špička, PhD; MD Maria Teresa Petrucci; MD Antonio P. Palumbo; MD Olga S Samoilova; Anna Dmoszynska; Prof. Kudrat M Abdulkadyrov; MD Michel Delforge, PhD; Bin Jiang; MD Maria-Victoria Mateos, PhD; MD Kenneth C. Anderson; MD Dixie-Lee Esseltine, FRCPC; Kevin Liu, PhD; William M Deraedt, PhD; MD Andrew Z. Cakana, FRCPath; MD Helgi van de Velde, PhD; MD Paul Gerard Guy Richardson

Datum přednesení příspěvku: 12. 12. 2011